West Pharmaceutical Services, Inc.
Bear Case (25th pct.)
-77.0% vs price
Base Case (Median)
-71.1% vs price
Bull Case (75th pct.)
-66.0% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $28.67 | -91.7% | High (40%) |
| PE Comparable | $174.03 | -49.8% | Medium (25%) |
| Growth Trajectory DCF | $114.93 | -66.8% | Medium (20%) |
| Graham Number | $87.92 | -74.6% | Medium (40%) |
| EV/EBITDA | $100.08 | -71.1% | Medium (20%) |
| EV/FCF | $120.86 | -65.1% | Medium (20%) |
| Earnings Power Value | $71.43 | -79.4% | Medium (50%) |
Based on 7 out of 8 methods, WST appears overvalued at the current price of $346.61. The base case fair value of $100.08 implies 71.1% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.